Search Results
152 items found for "cancer immune checkpoints"
- 📰 GPCR Weekly News, January 22 to 28, 2024
parahaemolyticus Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer
- Nanobodies: New Dimensions in GPCR Signaling Research
Generation, selection and functional expression: Nanobodies can be obtained by immunizing a camelid and
- 📰 GPCR Weekly News, October 30 to November 4, 2023
and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer
- Domain Therapeutics Raises $42m Series A Financing
"Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology
- 📰 GPCR Weekly News, January 30 to February 5, 2023
Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer
- Glyco-sulfo hotspots in the chemokine receptor system
these PTMs in the chemokine receptor system which may ultimately allow for new precise targeting of the immune
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company
- 📰 GPCR Weekly News
Discovery Collaboration Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology
- 📰 GPCR Weekly News, April 17 to 23, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, May 1 to 7, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, May 8 to 14, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, January 1 to 7, 2024
strengthens leadership team to spearhead global development and North American expansion as the leading GPCR immuno-oncology